Publication: Antimicrobial Agents and Chemotherapy
Abstract
Linezolid is effective against multidrug-resistant Gram-positive infections, but its population pharmacokinetic profile had not been characterized in critically ill Chinese children, limiting optimal dosing in pediatric intensive care. This prospective study in 63 critically ill pediatric patients used UPLC-MS/MS to measure linezolid plasma levels and built a population pharmacokinetic model with Phoenix NLME, then used Monte Carlo simulation to evaluate dosing regimens against a therapeutic target of AUC/MIC greater than 80. Body weight and aspartate aminotransferase were the most significant covariates, and increasing the dosing regimen to 15 mg/kg every 6 hours markedly improved target attainment at higher MIC values compared with standard dosing. The resulting population pharmacokinetic model and optimized dosing regimen support more effective linezolid therapy in critically ill pediatric patients.
Author(s): Yang M, Zhao L, Wang X, Sun C, Gao H, Wang X, Qian S
Published: February 8, 2021
Phoenix NLME: Optimizing Dosing for Critically Ill Children
Phoenix NLME’s population model and simulation supported a higher, more frequent linezolid dosing regimen for critically ill pediatric patients in this study. Phoenix NLME is also available through RsNLME, bringing population PK/PD modeling into R for teams who prefer that environment, within a Phoenix platform designed to move teams from data to decision in a fraction of the time.
